The European PRP market is expanding, driven by its efficacy in treating osteoarthritis and sports injuries, with the UK leading growth.
The market for platelet rich plasma (PRP) Europe is expected to reach US$ 37.5 Mn in 2016, up from US$ 35.3 Mn in 2015. Adoption of platelet rich plasma in treating musculoskeletal injuries, including tennis elbow, Achilles tendinopathy, and plantar fasciitis, will continue to drive revenues. PRP therapy is also gaining traction in treating sports-related and geriatric injuries, owing to its minimally invasive procedure and quicker recovery time.
By product type, PRP kits will continue to outsell instruments, accounting for over 75% revenue share of the market in 2016. Among the various platelet rich plasma kits, autologous kits will account for the highest demand on the basis of blood type, representing a market value worth US$ 24.2 Mn. P-PRF kits—valued at US$ 10 Mn in 2015—will witness the highest growth by end-product type, increasing at 8.6% in 2016.
To remain ‘ahead’ of your competitors, request for a sample @ https://www.futuremarketinsights.com/reports/sample/rep-eu-1599
By application, adoption of PRP therapy will continue to remain highest in the treatment of knee and elbow injuries. While knee application segment revenues will grow by 7.2%, elbow application segment revenues are projected to grow by 6.3%. Use of PRP therapy in the treatment of ever-increasing incidences of osteoarthritis and tennis elbow will gain further traction in 2016 and beyond.
PRP revenues in the UK—the largest market in Europe—will grow by 7.3% in 2016, an increase of 0.20% from the 7.1% growth in 2015. High prevalence of sports-related incidents in the U.K., combined with high awareness about the benefits of PRP therapy among healthcare community and patients, will continue to fuel the growth of the market in the country.
France will maintain its position as the second largest market for PRP in Europe, growing by 6.5% in terms of revenues in 2016. France is home to subsidiaries and distributors of several PRP players, such as Biomet, Inc., DePuy Synthes, Inc., and Stryker Corporation and a range of highly innovative products are available in the market.
Johnson & Johnson Inc. and Stryker Corporation are the established players in the Europe PRP market. Johnson & Johnson’s PEAK™ Platelet Rich Plasma System and Stryker Corporation’s RegenKit THT Autologous Platelet-rich Plasma (A-PRP) will continue to witness sizeable sales in 2016. Arthrex – Arthrex Angel System™ from Arthrex Inc. and GPS® III Platelet Separation System by Zimmer Biomet Holdings Inc. will also account for substantial revenue share of the Europe PRP market.
For Information On The Research Approach Used In The Report, Request TOC@ https://www.futuremarketinsights.com/toc/rep-eu-1599
Long-term Outlook: The PRP market in Europe is expected to increase at a CAGR of 6.6% during the forecast period 2016-2024. The UK will continue to be at the forefront of overall demand, with France and Germany accounting for sizeable market share. While FMI maintains a positive outlook on the Europe PRP market, challenges, including lack of standardisation in preparation and dosage of autologous blood concentrate, and uncertainty about therapy efficacy can impede growth during the forecast period.
Note to Editors and Journalists: Analysts who have compiled this report are available for interviews and quotes at press@futuremarketinsights.com
About the Healthcare Division at Future Market Insights
Future Market Insights facilitates corporates, government, investors, and associated audiences in the healthcare sector to identify and accentuate vital aspects applicable to product strategy, regulatory landscape, technology evolution, and other crucial issues to achieve sustainable success. Our unique approach to gathering market intelligence equips you in devising innovation-driven trajectories for your business. Know more about our sector coverage here
Explore FMI’s Extensive Coverage on Healthcare Domain
Orthopaedic Imaging Equipment Market The global Orthopedic Imaging Equipment Market was valued at US$ 9.8 Bn in 2021 and is expected to reach US$ 14.6 Bn by 2031.
Cellulite Treatment Market The global Cellulite Treatment Market is set to enjoy a valuation of US$ 3.3 Bn in 2022, and is predicted to expand at an impressive CAGR of 7.8% to reach a valuation of US$ 5.2 Bn by 2028.
Enzyme Replacement Therapy Market The global Enzyme Replacement Therapy Market is set to be valued at US$ 9.3 Bn in 2022, and is predicted to expand at a CAGR of 6.7% to attain a net worth of US$ 13.8 Bn by the end of 2028.
About Future Market Insights (FMI)
Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, and has delivery centers in the UK, U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition.
Contact:
Future Market Insights,
1602-6 Jumeirah Bay X2 Tower,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
For Media Enquiries: press@futuremarketinsights.com
Website: https://www.futuremarketinsights.com/
Report: https://www.futuremarketinsights.com/reports/europe-platelet-rich-plasma-market
Press Release Source: https://www.futuremarketinsights.com/press-release/europe-platelet-rich-plasma-market
The article discusses the growing adoption of Platelet Rich Plasma (PRP) in Europe for treating osteoarthritis and tennis elbow.
PRP therapy is gaining popularity due to its minimally invasive nature and effectiveness in treating musculoskeletal and sports injuries.
The UK and France are leading in PRP adoption, with the UK showing the highest growth in the European market.
Explore more articles in the Research Reports category
